Curcuma, most notably Curcuma longa (turmeric), has a long history of traditional use in Ayurvedic and Chinese medicine for gastrointestinal conditions, including inflammatory bowel diseases such as colitis. More recently, scientific research has investigated curcumin, the primary active compound in turmeric, for its anti-inflammatory and antioxidant properties relevant to colitis. Multiple in vitro and animal studies have shown that curcumin can reduce inflammatory markers, suppress pro-inflammatory cytokines, and attenuate colonic tissue damage in models of ulcerative colitis and Crohn’s disease. Several small-scale human clinical trials have reported that curcumin supplementation, often as an adjunct to standard therapy, can improve remission rates and reduce disease activity in patients with ulcerative colitis. For example, a double-blind, placebo-controlled study (Hanai et al., 2006) found that curcumin, combined with standard therapy, significantly reduced relapse rates over six months compared to placebo. However, limitations include relatively small sample sizes, variability in formulations and dosages, and a lack of large-scale, long-term trials. The overall evidence suggests a moderate level of scientific support for Curcuma's use in colitis, particularly as an adjunct rather than a standalone therapy, but further research is needed for definitive conclusions.